Positron emission tomography (or PET) is a non-destructive imaging technique in nuclear medicine with several unique properties: high sensitivity, low radiation dose, possibility to correct data for attenuation and scatter (thus quantitative), radioactive labeling of natural substances or drugs with high specific radioactivities so that these can be used as tracers to monitor the pharmacokinetics of the non-radioactive compounds. Limitations are the spatial resolution of commercially available PET cameras, resulting in blurring or non-visibility of objects smaller than 1 mm, and the short half-lives of the commonly used PET radionuclides (< 2 h). Because of the combination of positron emitters, specific radiopharmaceuticals and quantitative data analysis, PET is frequently used to study the pharmacokinetics and pharmacodynamics of test drugs non-invasively in humans.
1
Positron Emission Tomography or PET is a medical imaging technique providing information on tissue biochemistry rather than anatomy (Paans et al., 2000; Cherry, 2001; Levin, 2005; Wang et al., 2005) . 1 The term tomography indicates that two-dimensional images are acquired of several adjacent cross-sections ("planes" or "slices") within the subject's body (Fig. 1 ). The word emission shows that these images are generated after intravenous injection of a radioactive compound (the "radiopharmaceutical") into the volunteer or the experimental animal (Fig. 1) . The radiopharmaceutical is transported throughout the body by the circulation and taken up by target organs resulting in the emission of externally detectable radiation. The emitted radiation is measured by a PET camera and used for imaging. The radiopharmaceuticals which are used in PET are marked with radionuclides which decay by the emission of positrons (Fig. 2) . Positrons are anti-electrons, i.e. particles with the same mass as an electron but a positive in stead of a negative charge. This form of radioactive decay is important both for image reconstruction and for the interpretation of PET images.
A PET camera does not detect the positrons themselves for their range of travel within tissue is too short (less than 2.5 mm). Rather, the camera detects the two gamma quanta which originate from the annihilation of these anti-electrons. When a positron meets a normal electron, the combined mass of the two particles is converted to energy in a process that is called annihilation. Annihilation of a positron results in the formation of two 511 keV photons which are emitted in anti-parallel (i.e. approximately 180 degrees opposite) directions (Fig. 2) . These high-energy photons leave the body and are counted by detectors in the PET camera. Electronic circuits connected to the detector rings ensure that events are only registered when two detectors are (virtually) simultaneously hit by a photon. This coincidence detection has important advantages: (1) a low background count rate and a good signal-to-noise ratio of the detector system; (2) no collimator (i.e. no lead shield with narrow holes) is required for position information, resulting in a high sensitivity of PET cameras compared to normal gamma cameras using single photon emitters; and (3) images can be corrected for attenuation and scatter of the radiation within tissue. This correction is accomplished by making a transmission scan of the subject (patient, volunteer or experimental animal), using an external ( 68 Ge/ 68 Ga) gamma source, or by making a CT scan. Emission images (acquired after injection of the radiopharmaceutical) can then be corrected for attenuation measured with the external source, on the condition that the subject does not move between acquisition of the transmission (or CT) and emission scans. Thus, biochemical and physiological processes can be measured quantitatively.
A fundamental limitation in the spatial resolution of PET images is the range of positrons within tissue (Levin et al., 1999;  Introduction on PET: Description of Basics and Principles 3 Phelps et al., 1975; Tai et al., 2005) . This varies from less than 1 mm for 18 F to 2.5 mm for 15 O, at the mean positron energy which is 40% of the maximum. Since the annihilation occurs at another location than the positron decay, the range traveled by the positron makes it impossible to estimate the decay position with absolute precision.
Since the elements carbon, nitrogen and oxygen have positronemitting isotopes ( 11 C, 13 N and 15 O, respectively), drugs and biomolecules can be labeled with a positron emitter without changing their chemical properties. These isotopes can also be prepared with high specific radioactivities. Metabolites, neurotransmitters, hormones and drugs can therefore be labeled with positron emitters and be used as tracers to monitor the pharmacokinetics of the endogenous substance (or the non-radioactive test drug). A high specific radioactivity is particularly important in the case of receptor ligands, enzyme inhibitors or transporter blockers binding to a limited number of sites.
The radionuclides which are commonly used in PET have very short half-lives ( 15 O: two minutes, 13 N: ten minutes, 11 C: 20 minutes, 18 F: 109.8 minutes, respectively). Transport of carbon-11, nitrogen-13 and oxygen-15 over large distances is therefore impossible. Such radionuclides should be produced locally. 11 C, 13 N, 15 O and 18 F are made by nuclear reactions (Table 1) .
11 C, for example, is made by irradiating nitrogen gas with protons. Protons of the right energy evoke the following nuclear reaction:
The particles (protons or deuterons) causing the reaction are accelerated by means of a cyclotron. Small, dedicated medical cyclotrons are 4 A. van Waarde ) are used to synthesize the desired radiopharmaceuticals (see Table 1 ).
Since the half-lives of positron-emitting radionuclides are short, only rapid labeling procedures can be employed for radiopharmaceutical production. Radiochemists are responsible for these production processes. Many compounds are labeled by a single-step reaction of a des-methyl precursor with 11 C-methyl triflate or 11 C-methyl iodide. The final product then contains a 11 C-labeled methoxy or N-methyl group. Fluorine substitutions on an aromatic ring using 18 F-fluoride are also frequently employed for labeling. Synthesis modules for the automated production of common radiopharmaceuticals (e.g.
18 F-FDG, 18 F-FLT, 18 F-DOPA, 13 N-ammonia, 11 C-acetate and labeled substances produced by 11 C-methylation) can be purchased from several suppliers.
The short half-lives of positron emitters can be considered as a disadvantage of PET, since a local cyclotron and facilities for radiopharmaceutical production are required and biological processes with slow kinetics (e.g. the binding of antibodies to their targets) cannot be examined. However, the rapid decay may also be considered as an advantage. Relatively high doses of a positron emitter (several hundreds of MBq) can be administered to a subject, allowing the acquisition of images with good counting statistics for about three half-lives. Because of the short half-life of the employed radioactivity, the total radiation burden for the subject (i.e. the integral of radioactivity over time) remains low. The radiation burden for an average PET scan is 1 to 3 mSv, an order of magnitude lower than the average radiation burden for a CT scan (10 to 20 mSv). PET scans can therefore be made in healthy volunteers and subjects can be scanned repeatedly, e.g. at baseline and at two different time points after ingestion of a test drug (see Fig. 3 ).
Each PET study requires the harmonious cooperation of chemists, pharmacists, physicists and physicians. The scanning protocol proceeds in a number of logical steps: (1) production of radioactivity; (2) preparation of the desired radiopharmaceutical; (3) purification, sterilization and quality control; (4) administration of the tracer to the experimental animal or the human subject; (5) data acquisition; (6) image reconstruction; (7) analysis of the data with tracer-kinetic models; and (8) reporting to the investigator or the physician of the patient.
Many physiological and biochemical processes can be quantified with a PET camera (see Table 2 ). These include: blood flow (tissue perfusion), blood volume in a region of interest, glucose consumption, amino acid transport, lipid metabolism (activity of choline kinase), oxidative metabolism (Krebs cycle activity), the rate of synthesis of various neurotransmitters (e.g. dopamine, serotonin), the regional distribution and density of many receptors (e.g. binding sites for dopamine, noradrenaline, serotonin, acetylcholine, bombesin, neurokinin), biomarkers of cellular proliferation (e.g. EGF receptor density, sigma receptor density, rate of incorporation of nucleosides into cellular DNA), biomarkers of inflammation (e.g. translocator protein density, binding sites for interleukin-2), the expression levels and activity of various transporters (e.g. P-glycoprotein, noradrenalin transport, iodine transport), and the activity of important enzymes (e.g. thymidine kinase, cyclooxygenase-2). Using specific radiopharmaceuticals, PET can be applied in various ways during the drug discovery process. First, PET has important applications in pharmacodynamics. Pharmacodynamics is the study of the effects of drugs in the healthy and diseased body, including the mechanism of action and the relationship between drug concentration and effect. PET is capable of measuring the metabolic response of tissues in the human body quantitatively, repeatedly and noninvasively which can speed up drug development and can significantly reduce the associated costs. In oncology, PET may be employed to assess the effectiveness of novel anti-cancer agents and to optimize therapeutic protocols, e.g. by measuring the effect of the drug on glucose consumption, amino acid uptake or nucleoside metabolism within tumor cells (Avril et al., 2007; Kumar et al., 2007; Aboagye et al., 2003; Boss et al., 2008) . During the development of CNS drugs, PET is often used to measure the dose-dependent occupancy of target receptors within the human brain by a non-radioactive test compound (van Waarde, 2000; Passchier et al., 2002; Wong et al., 2009; Talbot et al., 2002; Halldin et al., 2001 )(see Fig. 3 ). Employing the 8 A. van Waarde pharmacokinetic parameters can also be examined, e.g. the impact of inhibition of the plasma protein binding (Haradahira et al., 2000) , metabolic degradation (Tipre et al., 2006; Doudet et al., 1997) or excretion (Lu et al., 2000) of the test substance. A relatively novel concept regarding the role of PET in drug discovery is the contribution of this imaging technique to 'personalized medicine' (Eckelman et al., 2008; Pither, 2003; Smith, 2005) . Novel targeted anticancer drugs are often highly effective in a small subpopulation of patients, but the overall response rate is low. In order for these drugs to be effective, the target must be present during treatment. Radiolabeled peptides (or antibody fragments) and nuclear imaging techniques like PET can be applied to examine whether the target is expressed in the primary tumor or it metastases throughout the patient's body (Dijkers et al., 2008; Van de Wiele et al., 2008) . PET scans are more informative than biopsy samples, since there is no risk of sampling errors and inaccessible (or unknown) lesions can be visualized. By providing proof of the presence of the target, PET can assist in the selection of the proper therapy for the individual patient. Zr (half-life 3.27 d) and injected it into a tumorbearing mouse. Whole-body microPET scans were made of this animal at 24 h, 72 h and 168 h after injection. The contrast between the tumor (implanted into the right hindleg) and non-target organs showed a steady increase during the 168 h period.
The risk of application of costly therapies to non-responders (resulting in a dangerous loss of time and unwanted side effects) may be reduced and the success rate for the individual patient increased.
Because of the combination of positron-emitting radionuclides, specific radiopharmaceuticals and quantitative data analysis, PET offers unique possibilities to study drug pharmacokinetics and pharmacodynamics non-invasively in humans. Increasing cooperation between nuclear medicine specialists, basic scientists, and pharmaceutical companies will definitely lead to many future applications of PET in the drug discovery process.
